Top View
- CB2013 Committee and Board Disclosureauditlist 6.20.13
- In Their Words
- Amgen Brochure
- TRUEBLUE TRUEBLUE SNAPSHOT Who We Are
- Can Vaccine Development Be Safely Accelerated?
- Makers Took Big Price Increases on Widely Used U.S
- 1 in the United States District Court for the District Of
- Gilead Sciences Appoints Flavius Martin, MD As Executive Vice President, Research
- Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
- Amgen and Abbvie Agree to Settlement Allowing Commercialization of AMGEVITA ™
- Amgen Inc. (Exact Name of Registrant As Specified in Its Charter)
- Managing Costs and Care with Biosimilars
- Exhibit Guide Header
- Why Is Moderna Still So Pricey?
- Biogen Idec's Agenda
- Amgen V. Sanofi
- Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma
- EPO: Taking Some Comfort Johnson & Johnson
- Disclosures and Contributions
- Gilead Sciences, Inc. Incoming Letter Dated December 21, 2018
- The Largest Pharmaceutical Companies Worldwide Analysis of Key Financial Indicators for Fiscal Years 2017, 2018 and 2019 About the Study
- Immuno-Oncology Dominates Big Pharma's Deal Agenda
- Trends in Oncology Dealmaking
- Draft Abbvie Amicus Brief (Amgen V Sandoz)
- Ipr2019-00741 U.S
- Health Disparities Through Partnership Summary Report
- Faculty Disclosures
- News Release
- IPR2019-00740 Patent: 9,718,880
- Difference for ME.”
- 20200915 MED-Project Participant List.Xlsx
- Amgen Wins Arbitration and Awarded $150 Million Against Johnson & Johnson
- DIGITIZING HEALTHCARE Embracing Change
- The CMC Strategy Forum (July 20-21, 2016)
- Petition for Rehearing En Banc
- APPENDIX 1 BIOTECH COMPANIES in the U.S. AMGEN Biogen Chiron
- Consensus Reports on Gilead Sciences, Inc. and Amgen Inc
- National Lipid Association Annual Summary of Clinical Lipidology 2015 Disclosures
- Mark One) (X) QUARTERLY REPORT PURSUANT to SECTION 13 OR 15(D) of the SECURITIES EXCHANGE ACT of 1934
- Court Dismisses in Re Humira Antitrust Suit Against Abbvie, Including Early-Entry Reverse Payment and “Patent Thicket” Allegations
- Merck & Co Makes Biggest Oncolytic Virus Bet Since Amgen in 2011
- U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9
- AMGEN INC. V. SANOFI
- Gilead Sciences and Royalty Pharma Complete $525 Million Purchase from Emory University of Emtricitabine Royalty Interest
- United States Securities and Exchange
- Patent Litigation
- Humira Skyrizi Rinvoq Imbruvica Venclexta Botox Cosmetic
- In the United States District Court for the Northern District of Illinois
- Form 8-K Current Report Pursuant to Section 13 Or